STI571: A paradigm of new agents for cancer therapeutics

Michael J. Mauro, Michael O'Dwyer, Michael Heinrich, Brian Druker

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.

Original languageEnglish (US)
Pages (from-to)325-334
Number of pages10
JournalJournal of Clinical Oncology
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2002

Fingerprint

Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Clinical Trials
Imatinib Mesylate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

STI571 : A paradigm of new agents for cancer therapeutics. / Mauro, Michael J.; O'Dwyer, Michael; Heinrich, Michael; Druker, Brian.

In: Journal of Clinical Oncology, Vol. 20, No. 1, 01.01.2002, p. 325-334.

Research output: Contribution to journalArticle

Mauro, Michael J. ; O'Dwyer, Michael ; Heinrich, Michael ; Druker, Brian. / STI571 : A paradigm of new agents for cancer therapeutics. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 1. pp. 325-334.
@article{e3d6fe18937141d89c40b5f4e0a42b73,
title = "STI571: A paradigm of new agents for cancer therapeutics",
abstract = "STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.",
author = "Mauro, {Michael J.} and Michael O'Dwyer and Michael Heinrich and Brian Druker",
year = "2002",
month = "1",
day = "1",
doi = "10.1200/JCO.20.1.325",
language = "English (US)",
volume = "20",
pages = "325--334",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - STI571

T2 - A paradigm of new agents for cancer therapeutics

AU - Mauro, Michael J.

AU - O'Dwyer, Michael

AU - Heinrich, Michael

AU - Druker, Brian

PY - 2002/1/1

Y1 - 2002/1/1

N2 - STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.

AB - STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.

UR - http://www.scopus.com/inward/record.url?scp=0036139993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036139993&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.1.325

DO - 10.1200/JCO.20.1.325

M3 - Article

C2 - 11773186

AN - SCOPUS:0036139993

VL - 20

SP - 325

EP - 334

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -